Testing everolimus for stubborn vascular anomalies
Treatments studied
Part of Cancer, Genetic & congenital, Heart & circulation clinical trials.
This trial tests the drug everolimus for people with certain types of vascular anomalies (tumors or malformations in blood vessels) that have not improved with other treatments. It aims to see if everolimus can help shrink these growths or control their symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of a vascular tumor or malformation (such as hemangioendothelioma or Kasabach-Merritt syndrome) that has not responded to at least one prior treatment.
- You are at least 1 year old.
- You have a measurable lesion (tumor or mark) at least 1 cm in size that can be seen on a CT or MRI scan.
- You are generally able to care for yourself and are up and about for at least half the day (ECOG score 0, 1, or 2).
- You are not pregnant or breastfeeding, and if you could become pregnant, you agree to use effective birth control during the study and for 8 weeks after.
- Your blood counts, kidney and liver function are within safe limits, and you do not have uncontrolled infections, diabetes, or high cholesterol.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a drug called everolimus to see if it helps treat vascular malformations (abnormal clusters of blood vessels). It is for adults aged 18 to 65 who have been diagnosed by MRI and are able to take oral medication.
This Phase 3 study tests whether sirolimus helps control complex vascular anomalies that have not responded to standard treatments. It also checks safety by monitoring blood tests, organ function, and overall health during treatment.
This trial studies whether sirolimus (Rapamune®) can reduce problems from severe arteriovenous malformations (tangled blood vessel connections). It may help shrink the abnormal vessels or improve symptoms, by testing the medicine in people with certain AVM types.
This trial studies whether taking sirolimus once a week can improve blood vessel, lymph vessel, or mixed (venolymphatic) malformations. It may help reduce symptoms and lesion size, while also monitoring safety in children and adults.
This study looks at how patients with vascular anomalies (abnormal blood vessel growths) respond to certain medications. It aims to gather real-world information about their care to improve future treatment.
This trial studies whether everolimus can improve outcomes for people whose kidney transplant biopsy shows signs of a specific type of immune attack. It focuses on patients without certain antibodies and with particular biopsy findings, aiming to prevent rejection-related injury while balancing medication side effects.
Hear when a new Vascular Malformations trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.